{"id":"W4283328999","doi":"10.1097/01.hs9.0000843512.62237.dc","title":"S155: EFFICACY AND SAFETY RESULTS FROM ASCEMBL, A PHASE 3 STUDY OF ASCIMINIB VS BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER ≥2 PRIOR TYROSINE KINASE INHIBITORS: WK 96 UPDATE","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Bosutinib; Discontinuation; Tolerability; Internal medicine; Adverse effect; Imatinib; Myeloid leukemia; Nilotinib; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003853955,0.0009420795,0.001983852,0.0006142558,0.0003157092,0.001375645,0.001014753,0.001247723,0.00780628],"category_scores_gemma":[0.002798259,0.0004131554,0.003339364,0.0006576956,0.0003098699,0.0008487545,0.0004785777,0.002336634,0.002580989],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001033232,"about_ca_system_score_gemma":0.001353723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00140723,"about_ca_topic_score_gemma":0.004376193,"domain_scores_codex":[0.9990448,0.0004001987,0.0001285863,0.0001203876,0.0002169436,0.00008899968],"domain_scores_gemma":[0.9976059,0.0004918538,0.000960783,0.00011752,0.0003603733,0.0004635996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4614447,0.006102102,0.03314742,0.005945761,0.009779987,0.0003675238,0.0002619922,0.002391604,0.02369093,0.0004150642,0.04576221,0.4106907],"study_design_scores_gemma":[0.4256707,0.1845429,0.2527619,0.002480875,0.01661062,0.001860153,0.0001751412,0.002496313,0.01061297,0.0008267296,0.1017295,0.0002321889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8254874,0.08491761,0.002564193,0.006710573,0.001264861,0.003959455,0.05030875,0.0006257501,0.02416133],"genre_scores_gemma":[0.8739281,0.03524445,0.004561288,0.008528265,0.001800358,0.002456499,0.05686336,0.0002357925,0.01638192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00780628,"threshold_uncertainty_score":0.02611458,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01020433407372738,"score_gpt":0.2673810174070419,"score_spread":0.2571766833333145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}